The Lynx Group

Colleen Ross, RN, MSN, MHA, OCN


Authored Items

Advances in Bendamustine Clinical Trials

June 2013, Vol 4 No 4 - Uncategorized

Bendamustine is currently approved for the treatment of chronic lymphocytic leukemia (CLL), and many ongoing studies are investigating its efficacy in drug combinations. Data in the relapsed/refractory setting are promising regarding improved overall survival and manageable toxicities, such as reversible myelosuppression, nausea, and fatigue – nursing implications mandate careful patient [ Read More ]

Sign me up!